Russ Conroy - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Russ Conroy's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Russ Conroy
Verified
Assistant Editor, Cancer Network
Hillsborough
Beats
immigrant issues global health global development
Never say never.
Content
By Russ Conroy| ONCOLOGY journal Verified The European Commission has approved an extended indication for subcutaneous daratumumab (Darzalex) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) as a treatment for adults with newly diagnosed multiple myeloma (NDMM), according to a press release from the developer, Janssen-Cilag International NV.1 The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use recommending the daratumumab regimen’s...
By Russ Conroy| ONCOLOGY journal Verified Treatment with tarlatamab-dlle (Imdelltra) conferred benefits across various functional and symptom outcomes among patients with previously treated small cell lung cancer (SCLC), according to an analysis of patient-reported outcomes (PROs) from the phase 2 DeLLphi-301 trial (NCT05060016).1 Per European Organization for Research and Treatment of Cancer 30-item Quality of Life Questionnaire (EORTC-QLQ-C30) scores, the most severe symptoms at baseline included fatigue (36.2), insomnia (27.9),...
By Russ Conroy| ONCOLOGY journal Verified The European Commission has approved an extended indication for subcutaneous daratumumab (Darzalex) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) as a treatment for adults with newly diagnosed multiple myeloma (NDMM), according to a press release from the developer, Janssen-Cilag International NV.1 The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use recommending the daratumumab regimen’s...
Company Info
Cancer Network
Cancer Network is an online platform focused on providing oncology news and clinical expertise. It serves as a valuable resource for insights on cancer screening, early detection, diagnosis, treatment, and prevention. The platform hosts the journal *Oncology*, which delivers professional content aimed at healthcare providers involved in cancer care. As a comprehensive information hub, Cancer Network offers timely updates on advances in cancer research, treatment modalities, and clinical trials. It features articles and expert commentary on best practices in oncology care, along with educational resources that help healthcare providers stay informed about the latest developments in cancer management. The primary audience includes oncologists, oncology nurses, researchers, and other healthcare professionals seeking authoritative information to enhance patient outcomes.
Hillsborough, United States
+1 516-562-5000